Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Publikáció
A false sense of hypoxia: Pro‑tumorigenic VHL‑HIF2α dysregulation in clear cell renal cell carcinoma (Review).
2026. okt. 23.· Molecular medicine reports· PUBMED
Publikáció
Discovery of Potent and Selective VHL-Recruiting PROTAC Degraders Targeting EGFR with Improved Developability and Potent Anti-NSCLC Efficacy.
2026. okt. 8.· Journal of medicinal chemistry· PUBMED
Vizsgálat
Phase IIA Study of Belzutifan in EPAS1-, EGLN1-, or VHL-Mutant Erythrocytosis
2026. okt. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Publikáció
Targeting the nonenzymatic scaffold function of RIPK1 via a VHL-recruiting PROTAC synergizes with immunotherapy in melanoma.
2026. szept. 29.· European journal of medicinal chemistry· PUBMED
Preprint
Combined Loss of VHL and TSC1 Drives Clear Cell Renal Cell Carcinoma with Metabolic and Redox Reprogramming that Creates an NRF2 Dependency.
2026. szept. 28.· bioRxiv : the preprint server for biology· PUBMED
Publikáció
Beyond hypoxia and ccRCC: the expanding universe of VHL novel targets and next-generation therapeutics.
2026. szept. 9.· Biomarker research· PUBMED
Publikáció
4-2 VHL-Recruiting PROTAC Inhibits the Growth and Migration of Triple Negative Breast Cancer Cells by Triggering Pyroptosis Through Fas-Mediated IL-17 Signaling.
2026. szept. 1.· Drug development research· PUBMED
Publikáció
Exosomal miR-21-5p from ectopic endometrial stromal cells drives fibrosis progression in endometriosis through direct VHL targeting.
2026. aug. 12.· Human cell· PUBMED
Publikáció
Dual loss of VHL and RASSF1A enhances tumorigenicity in clear cell renal cancer.
2026. júl. 30.· Frontiers in oncology· PUBMED
Publikáció
Downregulation of PHB1 due to Loss of VHL Protein Expression Promotes the Malignancy Progression of Kidney Renal Clear Cell Carcinoma.
2026. júl. 24.· Frontiers in bioscience (Landmark edition)· PUBMED
Publikáció
Case Report: Diagnosis and treatment report and literature review of 2 cases of VHL-deficient renal cell carcinoma.
2026. júl. 21.· Frontiers in oncology· PUBMED
Publikáció
Targeting enolase isoenzyme 2 enables precision glycolysis inhibition in VHL-mutant renal cell carcinoma.
2026. júl. 14.· Cell death & disease· PUBMED
Publikáció
GID4-Recruiting PROTACs for BRD4 Degradation Overcome Resistance Driven by CRBN and VHL Deficiency.
2026. júl. 5.· Journal of medicinal chemistry· PUBMED
Publikáció
Synthetic essentiality of TRAIL/TNFSF10 in VHL-deficient renal cell carcinoma.
2026. júl. 1.· Proceedings of the National Academy of Sciences of the United States of America· PUBMED
Publikáció
YTHDC2 suppresses oral squamous cell carcinoma progression by inhibiting glutaminolysis via VHL/HIF-1α axis.
2026. jún. 29.· International journal of biological macromolecules· PUBMED
Preprint
Rescuing the Function of Missense-Mutated Tumor Suppressor VHL using Stabilizing Small Molecules.
2026. máj. 29.· bioRxiv : the preprint server for biology· PUBMED
Publikáció
Reduced Circulating HIF-1α, HIF-2α, HIF-3α, and VHL Levels in Patients With Pulmonary Arterial Hypertension.
2026. máj. 21.· Pulmonary circulation· PUBMED
Publikáció
Natural Products in Clear Cell Renal Cell Carcinoma: Rewiring the VHL-HIF Axis, Metabolic Plasticity, and Tumor-Immune Interactions.
2026. máj. 20.· International journal of molecular sciences· PUBMED
Publikáció
First-in-human ex-vivo validation of carbonic anhydrase IX-PET for high-risk renal cancer (CAT-VHL - PNRR-POC-2023-12377493).
2026. máj. 18.· Theranostics· PUBMED
Vizsgálat
A clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)
2026. máj. 12.· PHASE3 · RECRUITING· CTIS
Preprint
PBRM1-VHL cooperation rewires lipid and iron metabolism to promote ferroptosis resistance in clear cell renal cell carcinoma.
2026. máj. 6.· bioRxiv : the preprint server for biology· PUBMED
Publikáció
Molecular Glue cc-885 Inhibits VHL-Deficient Clear Cell Renal Cell Carcinoma via ETS1 Degradation.
2026. máj. 6.· Advanced science (Weinheim, Baden-Wurttemberg, Germany)· PUBMED
Publikáció
Clear Cell Chondrosarcoma With Somatic VHL Inactivation: A Case Report With Integrated Genomic and Transcriptomic Analysis.
2026. máj. 1.· Genes, chromosomes & cancer· PUBMED
Publikáció
Degrading TBK1 to disarm VHL-deficient renal cancer.
2026. ápr. 16.· Cell chemical biology· PUBMED
Publikáció
Dual FDG and Octreotide PET/CT Imaging in a Patient With Malignant Pheochromocytoma and VHL Gene Mutation.
2026. ápr. 15.· Clinical nuclear medicine· PUBMED
Publikáció
CDK6/4 inactivates BAP1 deubiquitinase destabilizing VHL to promote metastatic colonization in liver.
2026. ápr. 15.· Molecular cancer· PUBMED
Publikáció
VHL-recruiting PROTAC attenuates AKI-CKD transition via simultaneous degradation of Smad3 and stabilization of HIF-2α.
2026. ápr. 10.· Cell death & disease· PUBMED
Publikáció
Proliferation and Apoptosis Adaptor Protein 15 (PEA15), a Potential Oncogenic Regulator of VHL and HIF1A Identified through Proteomic Analysis in Hepatocellular Carcinoma.
2026. ápr. 8.· Cancer communications (London, England)· PUBMED
Publikáció
Emerging roles for the epigenetic modifiers PBRM1 SETD2 and BAP1 in clear cell renal cell carcinoma pathogenesis and prognosis beyond VHL.
2026. márc. 31.· Discover oncology· PUBMED
Publikáció
VHL synthetic lethality screens uncover CBF-β as a negative regulator of STING.
2026. márc. 12.· Nature communications· PUBMED